Search
Lanreotide
go.drugbank.com/drugs/DB06791ApprovedInvestigationalLanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome … This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor.
Products: Somatuline Autogel Prolonged Release Solution for Injection in a Pre-filled Syringe 120 mg, Somatuline Autogel Prolonged Release Solution for Injection in a Pre-filled Syringe 60 mgBenzhydrocodone
go.drugbank.com/drugs/DB15465ApprovedBenzhydrocodone is a benzylic prodrug of hydrocodone.[L4894] It was developed in an effort to reduce parenteral bioavailability of the active metabolite as a deterrent to abuse. … It was first approved by the FDA in February 2018 in combination with [acetaminophen] under the trade name Apadaz, marketed by KVK Tech and developed by KemPharm.[L7859,L7862]
Acetarsol
go.drugbank.com/drugs/DB13268ApprovedWithdrawnAcetarsol, with the molecular formula N-acetyl-4-hydroxy-m-arsanilic acid, is a pentavalent arsenical compound with antiprotozoal and antihelmintic properties. … [L2622] It was first discovered in 1921 by Ernest Fourneau at the Pasteur Institute. It was developed by Neolab Inc, and approved by Health Canada as an antifungal on December 31, 1964.
Iopanoic acid
go.drugbank.com/drugs/DB08946ApprovedWithdrawnIopanoic acid contains iodine and is useful as a contrast medium in cholecystography.
Categories: Compounds used in a research, industrial, or household settingBrexanolone
go.drugbank.com/drugs/DB11859ApprovedInvestigationalIn particular, the use of brexanolone in treating PPD is surrounded with promise because it acts in part as a synthetic supplement for possible deficiencies in endogenous brexanolone (allopregnanolone) … The development and availability of brexanolone for the treatment of PPD in adult females subsequently provides a new and promising therapy where few existed before [F4066].
Categories: Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator, Neuroactive Steroid Gamma-Aminobutyric Acid (GABA) A Receptor Positive ModulatorsRuxolitinib
go.drugbank.com/drugs/DB08877ApprovedInvestigationalRuxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. … It is a potent and selective inhibitor of JAK1 and JAK2,[A229698] which are tyrosine kinases involved in cytokine signalling and hematopoiesis.
Categories: Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexMelphalan
go.drugbank.com/drugs/DB01042ApprovedInvestigational[L40928] It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. … Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent.
Synonyms: p-N,N-bis(2-chloroethyl)amino-L-phenylalanine, p-N-Bis(2-chloroethyl)amino-L-phenylalaninePiperazine
go.drugbank.com/drugs/DB00592ApprovedVet approvedWithdrawnFirst used as a solvent for uric acid, the use of piperazine as an anthelmintic agent was first introduced in 1953. … Piperazine is an organic compound that consists of a six-membered ring containing two opposing nitrogen atoms.
Products: PIPERAZINA AL 10%, PIPERAZINA AL 20%Picosulfuric acid
go.drugbank.com/drugs/DB09268ApprovedInvestigationalPicosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. … The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been used in European countries for many years.[A33322]
Mixtures: AGAROL CON SABOR A FRAMBUESALabetalol
go.drugbank.com/drugs/DB00598ApprovedInvestigationalLabetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. … [L7730] Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984.[L7724]
Products: Labetalol HCl in Dextrose, Labetalol HCl in Sodium Chloride